Literature DB >> 20607084

Urinary incontinence in women: part 1 of a series of articles on incontinence.

Christian Dannecker1, Klaus Friese, Christian Stief, Ricarda Bauer.   

Abstract

BACKGROUND: Urinary incontinence can arise in a woman of any age. Its prevalence is between 10% and 40%. The main clinical problems in urogynecology are stress urinary incontinence (involuntary leakage of urine on exertion, sneezing, or coughing) and the overactive bladder syndrome (nycturia, pollakisuria, and urinary urgency with or without incontinence).
METHOD: Selective literature search, with special attention to large-scale studies and to the guidelines of the German Society of Obstetrics and Gynecology (Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, DGGG) and its Task Force on Urogynecology and Pelvic Floor Reconstruction (Arbeitsgemeinschaft Urogynäkologie und Beckenbodenrekonstruktion).
RESULTS: There are many diagnostic and therapeutic options, whose use should be based on the degree of the patient's suffering and on her motivation to be treated. Anticholinergic drugs are of established value in the treatment of overactive bladder. They are used in combination with possible lifestyle changes and bladder training. In some circum-stances, botulinum toxin injections can be considered as well. Stress incontinence should be treated conservatively (with pelvic floor training) before any surgical treatment is provided. The new tension-free vaginal tapes are just as effective as classic treatments, such as colposuspension, while being less invasive and enabling a more rapid recovery.
CONCLUSION: All women with urinary incontinence should undergo appropriate, specialized diagnostic evaluation and well-founded counseling in order to benefit from individualized treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20607084      PMCID: PMC2896999          DOI: 10.3238/arztebl.2010.0420

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  24 in total

Review 1.  Antimuscarinics for treatment of overactive bladder.

Authors:  Karl-Erik Andersson
Journal:  Lancet Neurol       Date:  2004-01       Impact factor: 44.182

2.  The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction.

Authors:  R C Bump; A Mattiasson; K Bø; L P Brubaker; J O DeLancey; P Klarskov; B L Shull; A R Smith
Journal:  Am J Obstet Gynecol       Date:  1996-07       Impact factor: 8.661

3.  Is the pelvic organ prolapse quantification system (POPQ) being used? A survey of members of the International Continence Society (ICS) and the American Urogynecologic Society (AUGS).

Authors:  W Auwad; R M Freeman; S Swift
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2004-05-18

4.  Burch colposuspension: a 10-20 year follow up.

Authors:  M Alcalay; A Monga; S L Stanton
Journal:  Br J Obstet Gynaecol       Date:  1995-09

Review 5.  Open retropubic colposuspension for urinary incontinence in women.

Authors:  M C Lapitan; D J Cody; A M Grant
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 6.  A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder.

Authors:  Linda Cardozo; Gunnar Lose; Donna McClish; Eboo Versi
Journal:  Acta Obstet Gynecol Scand       Date:  2004-10       Impact factor: 3.636

7.  The prevalence of urinary incontinence in women in four European countries.

Authors:  S Hunskaar; G Lose; D Sykes; S Voss
Journal:  BJU Int       Date:  2004-02       Impact factor: 5.588

8.  Urinary incontinence in French women: prevalence, risk factors, and impact on quality of life.

Authors:  Andrea Lasserre; Camille Pelat; Violaine Guéroult; Thomas Hanslik; Emmanuel Chartier-Kastler; Thierry Blanchon; Calin Ciofu; Emmanuel D Montefiore; Fabián P Alvarez; Juliette Bloch
Journal:  Eur Urol       Date:  2009-04-10       Impact factor: 20.096

9.  ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence.

Authors:  Kerry Avery; Jenny Donovan; Tim J Peters; Christine Shaw; Momokazu Gotoh; Paul Abrams
Journal:  Neurourol Urodyn       Date:  2004       Impact factor: 2.696

10.  A double-blind randomized controlled trial of electromagnetic stimulation of the pelvic floor vs sham therapy in the treatment of women with stress urinary incontinence.

Authors:  Peter J Gilling; Liam C Wilson; Andre M Westenberg; William J McAllister; Katie M Kennett; Christopher M Frampton; Deborah F Bell; Patricia M Wrigley; Mark R Fraundorfer
Journal:  BJU Int       Date:  2009-01-14       Impact factor: 5.588

View more
  6 in total

1.  Local estriol treatment.

Authors:  Matthias Wenderlein
Journal:  Dtsch Arztebl Int       Date:  2010-11-26       Impact factor: 5.594

2.  Short periods of observation.

Authors:  Jens W Bagner; Bernd Klosterhalfen; Thomas Otto
Journal:  Dtsch Arztebl Int       Date:  2010-11-26       Impact factor: 5.594

Review 3.  [Vaginal laser therapy for urinary incontinence and genitourinary syndrome of menopause : A review].

Authors:  C Ratz
Journal:  Urologe A       Date:  2019-03       Impact factor: 0.639

Review 4.  [Not Available].

Authors:  Abdelmounaim Qarro; Mohammed Asseban; Khalil Bazine; Mohammed Najoui; Jamaleddine Samir; Youssef Ouhbi; Amoqrane Beddouch; Mohammed Lezrek; Mohammed Alami
Journal:  Can Urol Assoc J       Date:  2014-01       Impact factor: 1.862

Review 5.  [Mid-urethral sling operations for stress urinary incontinence in women].

Authors:  J Kranz; S Schmidt
Journal:  Urologe A       Date:  2016-05       Impact factor: 0.639

Review 6.  The treatment of climacteric symptoms.

Authors:  Olaf Ortmann; Claus Lattrich
Journal:  Dtsch Arztebl Int       Date:  2012-04-27       Impact factor: 5.594

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.